Epstein Secrets

ing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI's pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

ainst heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line. "Obvi

low me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being ad

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for

had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w

owing a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoenebaum, Evercore ISI’s pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would greenlight the drug for